We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+9.76%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$210M
AUM Growth
-$50M
Cap. Flow
-$601K
Cap. Flow %
-0.29%
Top 10 Hldgs %
49.98%
Holding
57
New
3
Increased
11
Reduced
5
Closed
6
Avg Time Held
1.1 years
Top 10 Avg Time Held
0.6 years
Top 20 Avg Time Held
0.9 years

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$7.1M
2
CELG
Celgene Corp
CELG
+$5.66M
3
ZGNX
Zogenix, Inc.
ZGNX
+$5.6M
4
INCY icon
Incyte
INCY
+$5.08M
5
EXEL icon
Exelixis
EXEL
+$5.07M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$14.5M
2
BIIB icon
Biogen
BIIB
+$10.5M
3
SAGE icon
Sage Therapeutics
SAGE
+$4.17M
4
ASXC icon
Asensus Surgical, Inc.
ASXC
+$3.82M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$3.52M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CELG
1
DELISTED
Celgene Corp
CELG
$17.4M 8.27%
253,522
+64,000
+34% +$5.66M
2016 Q4
7 quarters
ILMN icon
2
Illumina
ILMN
$40.5B
$14.5M 6.9%
53,045
+6,785
+15% +$2.17M
2018 Q2
1 quarter
INCY icon
3
Incyte
INCY
$23B
$10.6M 5.03%
200,000
+74,025
+59% +$5.08M
2016 Q4
7 quarters
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$129B
$10M 4.76%
67,722
-15,500
-19% -$2.76M
2016 Q4
7 quarters
ARRY icon
5
DELISTED
Array Biopharma Inc
ARRY
$9.84M 4.68%
844,500
+150,000
+22% +$2.3M
2016 Q4
7 quarters
REGN icon
6
Regeneron Pharmaceuticals
REGN
$82B
$9.71M 4.61%
31,330
– –
2016 Q4
7 quarters
EXEL icon
7
Exelixis
EXEL
$15.6B
$9.57M 4.55%
704,534
+260,000
+58% +$5.07M
2016 Q4
7 quarters
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
$8.7M 4.13%
81,641
– –
2016 Q4
7 quarters
STML
9
DELISTED
Stemline Therapeutics, Inc.
STML
$7.46M 3.55%
585,930
+93,000
+19% +$1.49M
2017 Q1
6 quarters
LGND icon
10
Ligand Pharmaceuticals
LGND
$5.95B
$7.36M 3.5%
56,105
– –
2016 Q4
7 quarters
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$10.8B
$7.23M 3.44%
97,284
– –
2016 Q4
7 quarters
HALO icon
12
Halozyme
HALO
$13.8B
$5.97M 2.84%
428,633
– –
2016 Q4
7 quarters
AERI
13
DELISTED
Aerie Pharmaceuticals
AERI
$5.91M 2.81%
125,179
+110,400
+747% +$7.1M
2016 Q4
7 quarters
ADMS
14
DELISTED
Adamas Pharmaceuticals
ADMS
$5.67M 2.7%
370,000
– –
2016 Q4
7 quarters
KALV icon
15
DELISTED
KalVista Pharmaceuticals
KALV
$5.47M 2.6%
322,436
– –
2016 Q4
7 quarters
GILD icon
16
Gilead Sciences
GILD
$195B
$5.35M 2.54%
90,284
– –
2016 Q4
7 quarters
PBYI icon
17
Puma Biotechnology
PBYI
$543M
$5.07M 2.41%
144,300
+98,000
+212% +$4.73M
2017 Q4
3 quarters
ABMD
18
DELISTED
Abiomed Inc
ABMD
$4.55M 2.16%
13,200
– –
2018 Q2
1 quarter
ZGNX
19
DELISTED
Zogenix, Inc.
ZGNX
$4.18M 1.99%
+110,000
New +$5.6M
2018 Q3
0 quarters
SPPI
20
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$3.86M 1.84%
300,000
– –
2018 Q2
1 quarter
ALNY icon
21
Alnylam Pharmaceuticals
ALNY
$31.3B
$3.54M 1.68%
52,800
+16,000
+43% +$1.61M
2017 Q3
4 quarters
SHPG
22
DELISTED
Shire pic
SHPG
$3.48M 1.65%
25,000
– –
2017 Q4
3 quarters
NBIX icon
23
Neurocrine Biosciences
NBIX
$13.9B
$3.35M 1.59%
35,500
-128,000
-78% -$14.5M
2017 Q3
4 quarters
SRPT icon
24
Sarepta Therapeutics
SRPT
$1.88B
$3.34M 1.59%
27,000
– –
2017 Q2
5 quarters
GTHX icon
25
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2.88M 1.37%
72,000
– –
2017 Q3
4 quarters
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2018 Portfolio in Review

As of Q3 2018, International Biotechnology Trust held 57 positions worth $210M, down 19% from $260M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

International Biotechnology Trust's Q3 2018 filing shows 3 new, 11 increased, 5 reduced and 6 closed positions. Its largest new stake was Zogenix, Inc.: 110,000 shares worth $4.18M. The largest sale was Neurocrine Biosciences, an estimated $14.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • International Biotechnology Trust's largest Q3 2018 buy was Zogenix, Inc.: 110,000 shares worth $4.18M.
  • International Biotechnology Trust added most to Aerie Pharmaceuticals in Q3 2018, an estimated $7.1M increase.
  • International Biotechnology Trust's biggest Q3 2018 reduction was Neurocrine Biosciences, cutting an estimated $14.5M.
  • International Biotechnology Trust fully exited Biogen in Q3 2018, selling an estimated $10.5M.
  • International Biotechnology Trust's ten largest holdings make up 50% of its $210M portfolio in Q3 2018.
  • International Biotechnology Trust opened 3 new positions and closed 6 in Q3 2018.
  • International Biotechnology Trust's portfolio value fell 19% quarter-over-quarter to $210M.

Based on International Biotechnology Trust's 13F filing for Q3 2018, filed 13 Nov 2018.